NSCLC - Platinum or not

Lung Cancer

Volumn 47, Issue 3, 2005, Pages 381-383

  Androulakis, Nikos ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM;

ASTHENIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT;

EID: 13844271680     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.11.010     Document Type: Editorial

References (25)

1. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials Br J Med 311 1995 899 909
2. M.H. Cullen, L.J. Billingham, and C.M. Wooddroffe Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life J Clin Oncol 17 1999 3188 3194
3. C.C. Earle, and W.K. Evans Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small cell lung cancer Br J Cancer 80 1999 815 820
4. T. Le Chevalier for the IALT Investigators Results of the randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs. no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2003 2 [Abstr. 6]
5. L. Novakova, L. Novakova, and L. Petruzelka Gemcitabine plus cisplatin (Gcis) versus gemcitabine plus carboplatin (Gcarb) in patients with stage IIIB and IV non-small cell lung cancer (NSCLC): final results of Czech Lung Cancer Cooperative Group phase III randomized trial Proc Am Soc Clin Oncol 21 2002 307a [Abstr. 1225]
6. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small cancer N Engl J Med 346 2002 92 98
7. K. Kelly, J. Crowley, and P.A. Bunn Jr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group J Clin Oncol 19 2001 3210 3218
8. R. Rosell, U. Gatzemeir, and D.C. Betticher Phase III randomized trial comparing paclitaxel/carboplatin in patients with advanced non-small cell lung cancer: a cooperative multicenter trial Ann Oncol 13 2002 1539 1579
9. F. Fossella, R.J. Pereira, and J. von Pawel Randomized, Multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small cell lung cancer. The TAX 326 Study Group J Clin Oncol 21 2003 3016 3024
10. V. Georgoulias, E. Papadakis, A. Alexopoulos, X. Tsiafaki, A. Rapti, and M. Veslemes Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial Lancet 357 2001 1478 1484
11. P. Kosmidis, N. Mylonakis, C. Nicolaides, C. Kalophonos, E. Samantas, and J. Boukovinas Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomised trial J Clin Oncol 20 17 2002 3578 3585
12. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 2004 [in press].
13. C. Gridelli, C. Gallo, and F.A. Shepherd Gemcitabine plus Vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 2003 3025 3034
14. E.F. Smit, J.P.A.M. van Meerbeeck, P. Lianes, Ch. Debruyne, C. Legrand, and F. Schramel Three-arm randomized study of two cisplatin based regimens and paclitaxel plus gemcitabine in advanced non small cell lung cancer: a phase III trial of the European organization for research and treatment of cancer. Lung Cancer Group EORTC 08975 J Clin Oncol 21 2003 3909 3917
15. V. Alberola, C. Camps, and M. Provencia Cisplatin plus gemcitabine versus a cisplatin based triplet versus non platinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group Phase III Randomized Trial J Clin Oncol 21 2003 3207 3213
16. E. Laack, N. Dickgreber, and T. Muller Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer. From the German and Swiss Lung Cancer Study Group J Clin Oncol 22 2004 2348 2356
17. Y.-M. Chen, R.-P. Perng, and Y.-C. Lee Paclitaxel plus carboplatin compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective a randomised phase II study of combination chemotherapy against inoperable non-small cell lung cancer previously untreated Ann Oncol 13 2002 108 1115
18. N. Yamamoto, M. Fukuoka, and S.-I. Negoro Randomized phase II study of docetaxel/cisplatin vs. docetaxel/irinotecan in advanced non-small cell lung cancer: a West Thoracic Oncology Group Study (WJTOG 9803) Br J Cancer 90 2004 87 92
19. R.P. Abratt, A. Szczesna, and K. Mattson Vinorelbine (NVB)-Carboplatin (CBDCA) vs. non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patients benefit analysis Proc Am Soc Clin Oncol 23 2004 619 [Abstr. 7016]
20. Y.-M. Chen, R.-P. Perng, and J.-F. Shih A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously treated Lung Cancer 47 2005 373 380
21. T. Le Chevalier, D. Brisgand, J.C. Soria, J.Y. Douillard, J.L. Pujol, and P. Ruffie Long term analysis of survival in the European randomised trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer Oncologist 6 Suppl 1 2001 8 11
22. R.C. Lilenbaum, J. Herndon, M. List, C. Desch, D. Watson, and J. Holland Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomised trial of efficacy, quality of life (QOL), and cost-effectiveness Proc Am Soc Clin Oncol 2002 [Abstr. 2]
23. V. Georgoulias, A. Ardavanis, and M. Agelidou Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial J Clin Oncol 22 2004 2602 2609
24. P.A. Kosmidis, M.A. Dimopoulos, and C. Syrigos Gemcitabine (G) vs. gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer and PS 2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group Proc Am Soc Clin Oncol 23 2004 627 [Abstr. 7058]
25. J.R. Rigas, M. Carey, and B. Cole Multicenter Web-based phase III study to test the survival equivalence of non-platinum-based (NPB) vs. platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC). The Dartmouth NPB Chemotherapy Trial (DO112) Proc Am Soc Clin Oncol 23 2004 631 [Abstr. 7071]